HNSA-5487

About Hansa Biopharma

Hansa Biopharma is a Nasdaq Stockholm-listed company (HNSA) focused on developing and commercializing first-in-class immunomodulatory therapies for rare immunological conditions. Its core achievement is the development and commercialization of imlifidase, a first-in-class IgG-cleaving enzyme approved in the EU for desensitization in kidney transplantation. The company's strategy leverages its unique enzyme technology platform to expand into acute autoimmune diseases and desensitization for advanced therapies, aiming to transform care in areas of critical unmet medical need.

Therapeutic Areas